CLOs on the Move

Epirium Bio

www.epirium.com

 
Epirium Bio is a clinical-stage biopharmaceutical company developing therapeutics that promote mitochondrial biogenesis and function through a novel mechanism of action discovered by the company.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.epirium.com
  • 4110 Campus Point Court
    San Diego, CA USA 92121
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Brampton Cosmetic Surgery

Brampton Cosmetic Surgery is a Brampton, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Premera

Premera is a Mountlake Terrace, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Clovis Oncology

Clovis Oncology is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aquatic Biotechnologies Inc

Aquatic Biotechnologies Inc is a Camarillo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tyra Biosciences

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. TYRA is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. TYRA is advancing multiple product candidates toward the clinic including its lead product candidate TYRA-300, an FGFR3 inhibitor with an initial focus on patients with bladder cancer, and TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma who have developed drug resistance mutations from existing FGFR inhibitors.